Pacific Therapeutics which Focuses on Drugs for Fibrosis Scarring and ED Announces Non-brokered Private Placement - Video News Alert on InvestmentPitch.com

February 26, 2015 4:54 PM EST | Source: InvestmentPitch Media

Vancouver, British Columbia--(Newsfile Corp. - February 26, 2015) - Pacific Therapeutics (CSE: PT) (OTCPINK: PCFTF) (Frankfurt: 1P3) has announced a non-brokered private placement of up to 2 million units at $0.05 to raise up to $100,000. The company is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets.

InvestmentPitch.com has produced a "video news alert" discussing Pacific Therapeutics. If this link is not enabled, please visit www.InvestmentPitch.com and enter "Pacific Therapeutics" in the search box.

If you cannot view the video above, please visit:
http://www.investmentpitch.com/video/0_j8xsrv76/Pacific-Therapeutics-CSE-PT-Announces-a-non-brokered-private-placement

The company's strategy includes reformulating approved drugs to increase efficacy and patient compliance, while reducing side effects, as well as completing the further clinical testing, manufacturing and other regulatory requirements sufficient to seek marketing authorizations. This strategy may reduce the risk, time and cost of developing therapies by avoiding the risks associated with basic research and the use of compounds with unknown safety and toxicity profiles.

The company's lead programs focus on diseases of excessive scarring or fibrosis, and erectile dysfunction, both $1 billion plus market opportunities.

Worldwide, there are more than 5 million people living with Idiopathic Pulmonary Fibrosis, which kills more patients per year than either prostate or breast cancer.

In 2012, the total market for drugs to treat erectile dysfunction exceeded $4.3 billion. Pacific Therapeutics' Oral Disintegrating Tablet formulation is a premium product that is fast-acting, with the potential to reduce common side effects. This formulation is expected to fill a niche not serviced by big pharma and generics, as 70% of patients prefer drugs in an oral disintegrating form.

The company will be initiating a pivotal Bioequivalence trial, and with anticipated successful results the company will begin the application for marketing approval in Europe.

The company has also engaged Small-Cap Invest, a Frankfurt-based financial service company, to develop investor and public relations across Europe, and ultimately facilitate the commercialization of the company's therapies in European markets. Small-Cap Invest has agreed to provide these services for 6 months and as a vote of confidence in Pacific Therapeutics, is accepting 250,000 stock options with an exercise price of $0.25 per share, a very healthy premium to today's price, which is $0.03.

For more information please visit the company's website www.pacifictherapeutics.com, or contact Douglas Unwin, President & CEO at 604-738-1049 or email doug.unwin@pacifictherapeutics.com.

About InvestmentPitch

InvestmentPitch.com, a multimedia company that provides a combined solution for creating and hosting financial video content, and distributing it across multiple platforms to investors and financial professionals, specializes in producing short three minute videos based on significant news releases, research reports and other market information. Please visit InvestmentPitch.com and browse the extensive library of investment videos.

CONTACT:
InvestmentPitch.com
Barry Morgan, CFO
bmorgan@investmentpitch.com

info